The FDA has approved tigecycline (Tygacil™, Wyeth), an intravenous antibiotic with a broad spectrum of antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) to treat complicated skin and skin-structure and intra-abdominal infections in adults. This is the first antibiotic approved in a new class called glycylcyclines, which overcome key mechanisms of resistance that have affected antibiotic [...]
This study presented at the International Society of quality of Life demonstrated that children taking Omnicef drug were 28 percent more likely to finish all their medication than those taking Augmentin antibiotic. Parents regarded generic Omnicef a significantly effective, easier-to-use medicine in the antibiotic list to treat acute otitis media. In this study, researchers compared [...]
Oral antibiotic omnicef (cefdinir) is indicated for pediatric patients (ages six months to 12 years) in the form of suspension to treat from mild to moderate infections: acute bacterial otitis media, Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only) and Moraxella catarrhalis (including beta-lactamase-producing strains); and pharyngitis/tonsillitis due to Streptococcus pyogenes. Generic Omnicef [...]
Abbott Laboratories announced today that a new FDA approved 250mg/5m dosing option of the antibiotic Omnicef (generic cefdinir) Oral Suspension (OS) is available for use in pediatric patients six months to 12 years old. The more concentrated 250mg/5mL formulation allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using [...]
